GlassScriptPhysician profile
Clint Nacar
NPI 1609466259
$12,120.26
in general payments reported to CMS, 2019-2025
21 companies · $3,467 in 2025
The $3,467 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.19 · 2022: $1,120 · 2023: $3,659 · 2024: $3,859 · 2025: $3,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $619 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,353.01 |
| Travel and Lodging | $619.03 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,181.39 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,855.37 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,210.97 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,039.84 | 2022-2025 | Caplyta |
| Alkermes, INC. | $888.86 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $637.20 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $597.05 | 2022-2025 | Rexulti |
| Almatica Pharma LLC | $570.22 | 2022-2024 | Loreev Xr, Sertraline Hcl, Citalopram |
| Vanda Pharmaceuticals INC. | $568.36 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $543.66 | 2024-2025 | Qelbree |
| Indivior INC. | $415.08 | 2022-2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $394.92 | 2022-2024 | Uzedy, Austedo |
| Corium, LLC | $367.23 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $280.01 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $189.51 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $101.18 | 2024-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $94.92 | 2022 | |
| Biogen, INC. | $73.35 | 2024 | |
| Tempus Ai, INC | $72.12 | 2024 | Tempus Pixel |
| Noven Therapeutics, LLC | $21.65 | 2025 | Xelstrym |
| Neuronetics, INC. | $17.37 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Nacar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.